Have you or your loved ones been diagnosed with bladder cancer?

You may be eligible to participate in a bladder cancer clinical trial.

Have you or your loved ones been diagnosed with bladder cancer? You may be eligible to participate in a bladder cancer clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Bladder Cancer Clinical Trial
NCT03081858 | Phase 1 phase 2 | Interventional
Lipac Oncology LLC
Sponsored by
Lipac Oncology LLC

Have you or your loved ones been diagnosed with bladder cancer?

You may be eligible to participate in a bladder cancer clinical trial.

Have you or your loved ones been diagnosed with bladder cancer? You may be eligible to participate in a bladder cancer clinical trial.

Active not recruiting

Male & Female

18 - 85

Years old

This study has recruited 15 Participants

This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder. Part 1 of the study will enroll 6 subjects (3 per cohort) with low-grade, stage Ta transitional cell carcinoma (TCC) of the bladder who will receive escalating doses of paclitaxel formulated as TSD-001 every 2 weeks for 6 treatments until Dose Limiting Toxicity (or until the Maximum Deliverable Dose) is observed (Maximum Tolerated Dose established). Part 2 of the study will enroll an additional 10 subjects with low-grade, stage Ta (uni-or multifocal) TCC of the bladder who will receive weekly TSD-001 for 6 weeks at the highest nontoxic dose (i.e., MTD) established in part 1 of the study. May meet definition of low grade without histological tissue diagnosis if on cystoscopic assessment they have a solitary papillary tumor. Part 3 of the study will continue to track subjects enrolled in Parts 1 and 2 to determine rates of disease-free survival.